HR and neoplasm: In all, 18 patients (51%) of the full study group were in the 1st line of therapy at time of test initiation and 12 (48%) belonged to the HR+/HER2- cohort (Table 1); 6 (17%) patients had an HER2-amplified and 5 (14%) patients a triple negative tumor.